CNBC December 11, 2024
Novo Nordisk just got a step closer to significantly improving supply for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.
The Danish drugmaker’s parent company, Novo Holdings, got approval from European antitrust regulators last week to move forward with its proposed $16.5 billion buyout of U.S.-based drug manufacturer Catalent – a deal that had raised concerns among both rival drugmakers and lawmakers.
That leaves the U.S. Federal Trade Commission as the last hurdle Novo Holdings needs to overcome to cement the colossal deal, which it announced in February. Novo Holdings and Novo Nordisk said they expect the transaction to close at the end of the month.
Catalent is an attractive buyout target for Novo Holdings, which...
Today's Sponsors
Today's Sponsor